Multicenter,randomized,crossover clinical trial comparing the effects of Alogliptin and Sitagliptin in patients with type 2 diabetes

Multicenter,randomized,crossover clinical trial comparing the effects of Alogliptin and Sitagliptin in patients with type 2 diabetes - Comparison of Alogliptin and Sitagliptin in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007056

Enrollment

200

Registered

2012-01-12

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Administration of Alogliptin 25mg in the first 4 months followed by the administration of Sitagliptin 50-100mg for 4 months Administration of Sitagliptin 50-100mg in the first 4 months followed by the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes treated with Sitagliptin 50-100mg

Exclusion criteria

Exclusion criteria: 1)Patient who has a history of hypersensitivity against Alogliptin 2)Patient on insulin treatment 3)Patient with severe renal dysfunction or renal failure 4)Patient under 20 years old 5)Patient considered as inadequate by the principal investigator

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
plasma glucose, C-peptide, glucagon, urinary sugar	—

Countries

Japan

Contacts

Public ContactTomoko Nakagami

Tokyo Women's Medical University Third Department of Medicine

nakagami@dmc.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026